Revolution Medicines, Inc.
Developing oral RAS(ON) inhibitors for RAS-addicted cancers. Daraxonrasib is under FDA review for previously treated metastatic pancreatic cancer, with additional Phase 3 programs ongoing.
Oncology · Oral RAS(ON) inhibitors · NDA under FDA review / Phase 3